White Paper
Economic Burden of Respiratory Syncytial Virus (RSV) Infection Among Older Adults in Select Asia-Pacific Economic Cooperation (APEC) Countries
Nov 27, 2024
Download

Respiratory Syncytial Virus (RSV) is a highly contagious respiratory pathogen causing severe lower respiratory tract diseases, particularly in older adults (age ≥60 years). Annually, RSV accounts for around 5.2 million cases and 33,000 in-hospital deaths among older adults in high-income countries. Factors like immune decline, lung aging, and comorbidities increase susceptibility.

The economic impact of RSV on healthcare systems in high-income Asia-Pacific Economic Cooperation (APEC) countries (China, Japan, South Korea, Canada, Singapore, New Zealand, Australia, Hong Kong, Taiwan) is significant but challenging to quantify due to insufficient epidemiological and healthcare resource data for older adults. Routine RSV testing is uncommon due to non-specific symptoms overlapping with other infections. Diagnosis often relies on local epidemiology rather than lab tests, leading to inconsistent testing methods.

Our study estimated the clinical and economic burden of RSV among older adults in high-income APEC countries. A literature review identified evidence on the incidence and costs associated with RSV hospitalizations. In 2023, RSV caused approximately 778,000 hospitalizations and USD 2.8 billion in costs. The highest estimated burden was seen in China, followed by Japan and Canada. On average, 1 in 500 older adults were hospitalized annually, with hospitalization costs ranging from USD 2,735 in New Zealand to USD 12,826 in Canada.

Therefore, there is a need for an urgent strategic mitigation plan to address the growing burden of RSV infection. Our study's data will guide future prevention programs and be crucial for regulatory decision-making and healthcare planning. These measures will help ease the RSV burden on healthcare systems and economies. Read the full white paper for more insights.

Contact Us